Date: 07/09/2026

To
Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

Symbol: BALPHARMA

To
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400001

Scrip Code: 524824

Sub: Allotment of 10,00,000 Warrants to the Promoter of the Company on Preferential Basis

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is in continuation of the earlier intimations made by the Company in connection with the proposed issue of Convertible Warrants on a preferential basis.

Pursuant to the Regulation 30 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with relevant circulars thereto issued by Securities and Exchange Board of India from time to time ("SEBI Listing Regulations") and in compliance with the Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations") and approval accorded by the Shareholders of Bal Pharma Limited ("the Company") through Postal Ballot on 08th August, 2026 and In-Principle approval granted by the National Stock Exchange of India Limited (vide its letter bearing reference no NSE/LIST/56262) and BSE Limited (vide its letter bearing reference no LOD/PREF/GB/FIP/749/2026-27) on 04th September 2026, and upon receipt of ₹2,10,00,000/- (Rupees Two Crores Ten Lakhs only) i.e. the 25% of the total amount payable towards subscription of the warrants from the allottee, we wish to inform that the Board of Directors of the Company vide their Resolution passed through Circulation (01/2026-27) today i.e. Monday, 07th September, 2026 has considered , approved and Confirmed the allotment of 10,00,000 (Ten Lakh) Warrants on a preferential basis to Mr. Shailesh Siroya, Promoter of the Company, at an issue price of ₹84/- (Rupees Eighty-Four only) per Warrant, aggregating to ₹8,40,00,000/- (Rupees Eight Crore Forty Lakh only), on such terms and conditions as approved by the Members and in accordance with the applicable provisions of law.

Corporate Office
+91 80 4137 9500
info@balpharma.com
5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

Further, the aforesaid warrant(s) are being allotted in electronic form and are subject to lock-in, in compliance with the applicable provisions of SEBI ICDR Regulations. The conversion of warrants into equivalent number of equity shares of the Company can be exercised by the warrant holder at any time during the period of eighteen months from the date of allotment of Warrants i.e. 07th September 2026, in one or more tranches, upon payment of the remaining 75% of the amount payable against each such warrant before the last date of conversion of warrants.

Since the Company has allotted Convertible Warrants and not Equity Shares, there is no change in the paid-up Equity Share Capital of the Company pursuant to the aforesaid allotment of Warrants.

Upon exercise of the Warrants and payment of the balance consideration, the corresponding Equity Shares shall be allotted by the Company and shall rank pari passu in all respects with the existing Equity Shares of the Company.

The Equity Shares to be allotted upon conversion of the Warrants shall be listed on BSE Limited and National Stock Exchange of India Limited, where the existing Equity Shares of the Company are listed, subject to receipt of the requisite approvals from the respective Stock Exchanges and compliance with applicable laws and regulations.

The details in respect of the preferential issue, as required to be disclosed under Regulation 30 of the SEBI Listing Regulations, read with the SEBI Master Circular is set out below in Annexure – A.

Kindly take the above information on record.

Thanking You.

For Bal Pharma Ltd

Shreepada ML

Digitally signed by Shreepada ML
DN: cn=Shreepada ML, o, ou, email=sribhat111@gmail.com, c=US
Date: 2026.09.07 18:09:47 +05'30'

BAL PHARMA LTD CIN L85110KA1987PLC008368 BENGALURU

Shreepada ML
Company Secretary and Compliance officer
ICSI M No : A66681

Enclosure: Annexure A

BAL PHARMA LIMITED

Corporate Office
+91 80 4137 9500
info@balpharma.com
5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

Annexure-A

Details required under Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular

<table>
<tr><th>Sl No</th><th>Particulars</th><th>Details</th></tr>
<tr><td>1</td><td>Type of securities proposed to be issued</td><td>Convertible warrants</td></tr>
<tr><td>2</td><td>Type of issuance</td><td>Preferential issue</td></tr>
<tr><td>3</td><td>Total number of securities proposed to be issued or the total amount for which the securities will be issued</td><td>10,00,000 (Ten Lakh) Warrants at an issue price of ₹84/- (Rupees Eighty-Four only) per Warrant, aggregating to ₹8,40,00,000/- (Rupees Eight Crore Forty Lakh only).
Each Warrant is convertible into, or exchangeable for 1 (One) equity share of the Company of face value Rs. 10 (Rupees Ten only) at a premium of Rs. 74 (Rupees Seventy-Four only) per share.</td></tr>
<tr><td>4</td><td colspan="2">Additional Information in case of preferential issue:</td></tr>
<tr><td>a</td><td>Name of investor</td><td>Mr. Shailesh Siroya, Promoter of the Company</td></tr>
<tr><td>b</td><td>Post allotment of securities outcome of the subscription</td><td>Warrants are allotted to the following Allottee. Details of the shareholding of the Allottee in the Company, prior to and after the proposed preferential issue, are as under:
<table><tr><td>Particulars (Name of the Investors)</td><td>Pre-Preferential Allotment</td><td>Post-Allotment of Warrants pursuant to the Preferential Issue *</td></tr><tr><td>Mr. Shailesh Siroya</td><td>27,45,459 (17.24%)</td><td>37,45,459 (20.89%)</td></tr></table>
* The above shareholding has been arrived at on the assumption that the entire 10,00,000 Warrants allotted would be converted into Equity Shares</td></tr>
</table>

c	Issue Price/ allotted price (in case of convertibles)	₹84/- (Rupees Eighty-Four only) per Warrant. (including the warrant subscription price and exercise price)
d	Number of Investors	01 (One)
e	In case of Convertibles intimation on conversion of securities or on lapse of the tenure of the instrument	Each Warrant will be convertible into, or exchangeable for 1 (One) fully paid-up equity share of the Company of face value of Rs. 10 (Rupees Ten only), which may be exercised in one or more tranches during a period of 18 (eighteen) months commencing from the date of allotment of the Warrants i.e. 07th September 2026. In the event the Allottee does not exercise the Warrants within the aforesaid period, the unexercised Warrants shall lapse and the amount paid by the Allottee on the unexercised Warrants shall stand forfeited on such terms and conditions as approved by the Members and in accordance with the applicable provisions of law.

For Bal Pharma Ltd

Shreepada ML

Digitally signed by Shreepada ML
DN: cn=Shreepada ML, o, ou, email=sribhat111@gmail.com, c=US
Date: 2026.09.07 18:10:25 +05'30'

BAL PHARMA LTD
BENGALURU

Shreepada ML
Company Secretary and Compliance officer
ICSI M No : A66681